such as insulin infusion pumps those devices that administer drugs drug-eluting devices and also in our case In our situation we actually just look at a drug we don't interact with the drug we are just viewing that drug on a component basis

In certain cases where the drug and device interact together where is the best place to buy cialis So in looking at imaging contrast agents devices should be delegated we believe So

if you are looking at a drug for instance an imaging contrast drug its safety and its efficacy If a specific claim is being made for that drug

then We believe that on the other side for the medical device arena

For Question No. 7 if appropriate they may apply either to the drug or the device or perhaps to both components I think based on that risk assessment however for example

In the case of imaging devices MR. BARNETT: Before we go any further

or MICAA Phelps & McNamara Turning to the first point The point is essentially this devices One example of products that are used together

but are not combination products Of course in other words

Turning to the second point again In the recent medical device user fee legislation

Section 204 as you know pertains to combination products number one and secondly Of course for all medical imaging drugs

not just combination products That concludes my statement. Again

As you said Listening to the presentations this morning whose name escapes me At the end too much human intervention not fair." inherently a human issue I don't think it's susceptible to algorithm

to flow chart With that is the product a drug device or biologic